Related references
Note: Only part of the references are listed.Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry
Andrea Chiricozzi et al.
ALLERGY (2021)
Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals
J. M. Norlin et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension
M. J. Cork et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis A Phase 3 Randomized Clinical Trial
Eric L. Simpson et al.
JAMA DERMATOLOGY (2020)
Dupilumab and COVID-19: What should we expect?
Cataldo Patruno et al.
DERMATOLOGIC THERAPY (2020)
Quality of Life of Parents of Children with Atopic Dermatitis
Joanna Marciniak et al.
ACTA DERMATO-VENEREOLOGICA (2017)
Suicidal Ideation, Mental Health Problems, and Social Function in Adolescents with Eczema: A Population-Based Study
Jon A. Halvorsen et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization
Jonathan I. Silverberg et al.
PEDIATRIC ALLERGY AND IMMUNOLOGY (2013)
Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis
Marcia J. Slattery et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)
Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three
Joseph A. Odhiambo et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Changes in prevalence of asthma and allergies among children and adolescents in Italy: 1994-2002
C Galassi et al.
PEDIATRICS (2006)
Share Paper
